---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Target-HTN"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Target-HTN. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 72 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence/target-htn"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Target-HTN

<a id="heading-3.1.4"></a>

## 3.1.4 Target-HTN

<a id="heading-3.1.4.1"></a>

### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

#### Primary objective: safety, efficacy, and dose selection

> “To compare the safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, with placebo, and characterize dose-dependent safety and efficacy to inform dose selection in future trials.”
> “The Trial on the Safety and Efficacy of MLS-101 (Lorundrostat) in Patients With Uncontrolled Hypertension (Target-HTN) was designed to examine the safety and efficacy of lorundrostat at 5 different doses in participants with uncontrolled hypertension, with a specific aim of BP reduction among participants with obesity or suppressed renin.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.1-2"></a>

#### Registered purpose of the study

> “A randomized, double-blind, placebo-controlled, dose-ranging, Phase II study to evaluate the safety, efficacy, and tolerability of MLS-101 in Subjects With Uncontrolled Hypertension”

Source: [ClinicalTrials.gov NCT05001945](https://clinicaltrials.gov/study/NCT05001945)

<a id="topic-3.1.4.1-3"></a>

#### Company description of the trial objective

> “The trial was designed to evaluate the safety, efficacy, tolerability and dose response of orally administered lorundrostat for the treatment of uHTN and rHTN when used as add-on therapy to stable background treatment of two or more antihypertensive agents in 200 male and female subjects 18 years of age or older.”

Source: [Mineralys Therapeutics press release, Target-HTN JAMA publication (2023)](https://ir.mineralystx.com/news-events/press-releases/detail/26/mineralys-therapeutics-announces-jama-publication-of-full)

<a id="heading-3.1.4.2"></a>

### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

#### Sites in the United States

> “Target-HTN was a multicenter, prospective, randomized, placebo-controlled, dose-ranging clinical trial performed at 43 sites within the United States.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.2-2"></a>

#### Registered locations and study dates

> “This study has 44 locations”

Source: [ClinicalTrials.gov NCT05001945](https://clinicaltrials.gov/study/NCT05001945)

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2021-07-01” |
| Primary completion (actual) | “2022-09-07” |
| Study completion (actual) | “2022-10-07” |
| Other study ID number | “MLS-101-201” |
| Sponsor | “Mineralys Therapeutics Inc.” |

Source: [ClinicalTrials.gov NCT05001945](https://clinicaltrials.gov/study/NCT05001945)

<a id="topic-3.1.4.2-3"></a>

#### Enrollment and follow-up period

> “Between July 2021 and June 2022, 200 participants were randomized, with final follow-up in September 2022.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.2-4"></a>

#### Ethics approval

> “The institutional review boards at the clinical trial sites approved the study, and all participants provided written informed consent.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="heading-3.1.4.3"></a>

### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

#### Randomized, placebo-controlled, dose-ranging design

> “Randomized, placebo-controlled, dose-ranging trial among adults with uncontrolled hypertension taking 2 or more antihypertensive medications.”
> “In this multicenter, prospective, randomized, placebo-controlled, dose-ranging, double-blind clinical trial among adults with uncontrolled hypertension”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.3-2"></a>

#### Registered design details

| Field | Quoted record |
| --- | --- |
| Phase | “Phase 2” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Primary purpose | “Treatment” |

Source: [ClinicalTrials.gov NCT05001945](https://clinicaltrials.gov/study/NCT05001945)

<a id="topic-3.1.4.3-3"></a>

#### Prescreening, placebo run-in, and 8-week treatment period

> “Participants underwent 2 to 4 weeks of prescreening, a 2-week placebo run-in period to ensure eligibility, and then randomization and treatment for 8 weeks. A final visit was conducted 2 to 4 weeks following completion of the double-blind treatment (eFigure 1 in Supplement 2).”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.3-4"></a>

#### Single-blind placebo run-in by renin stratum

> “After successful screening, subjects with plasma renin activity (PRA) ≤1ng/mL/h began a single-blind (SB) run-in period of BID oral treatment with placebo (PBO) in Part 1, and subjects with PRA >1ng/mL/h began a SB QD oral treatment with PBO in Part 2, while continuing on stable doses of background AHT medications.”

Source: [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)

<a id="topic-3.1.4.3-5"></a>

#### Two cohorts defined by plasma renin activity

> “An initial cohort of 163 participants with suppressed plasma renin (plasma renin activity [PRA] ≤1.0 ng/mL/h) and elevated plasma aldosterone (≥1.0 ng/dL) were enrolled, with subsequent enrollment of 37 participants with PRA greater than 1.0 ng/mL/h.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.3-6"></a>

#### Interim analyses and discontinuation of the two lowest doses

> “An independent data and safety monitoring board performed an interim analysis in January 2022, and randomization to the 2 lowest doses of lorundrostat (12.5 mg once daily and 12.5 mg twice daily) was discontinued due to lack of consistent meaningful reduction of BP.”
> “An additional interim analysis was performed following the last participant visit from cohort 1 and full enrollment of cohort 2 to guide dose selection in future studies.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.3-7"></a>

#### Weekly visits and blood pressure measurement schedule

> “Following randomization, all participants’ study visits were conducted at weeks 1 through 8.”
> “Twenty-four-hour ambulatory BP monitoring was measured at baseline and once again prior to the 8-week visit.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.3-8"></a>

#### Trial oversight and sponsor role

> “The trial protocol was designed by Mineralys Therapeutics.”
> “An independent data monitoring committee oversaw patient safety. Cytel performed the statistical analysis, and the Cleveland Clinic Coordinating Center for Clinical Research (C5Research) independently confirmed the primary end-point analysis.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="heading-3.1.4.4"></a>

### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

#### Uncontrolled blood pressure on 2 or more antihypertensive medications

> “Patients were eligible for trial enrollment if they were older than 18 years with a systolic automated office BP (AOBP) of 130 mm Hg or greater while taking 2 or more antihypertensive medications for at least 4 weeks at maximally tolerated doses.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.4-2"></a>

#### Renin and aldosterone criteria for each cohort

> “Cohort 1 of the study enrolled participants with suppressed plasma renin (plasma renin activity [PRA] ≤1.0 ng/mL/h) and serum aldosterone level of 1.0 ng/dL or greater based on morning measurements, while cohort 2 enrolled participants with PRA of greater than 1.0 ng/mL/h.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.4-3"></a>

#### Key exclusion criteria

> “Key exclusion criteria included orthostatic hypotension, type 1 diabetes, concomitant use of an epithelial sodium channel inhibitor or MRA, estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2, morning serum cortisol level of less than 3 µg/dL, serum sodium level of less than 135 mmol/L, or hemoglobin A1c of 9% or greater.”
> “A systolic AOBP of 175 mm Hg or greater, diastolic BP of 100 mm Hg or greater, or serum potassium level greater than 5.2 mmol/L was exclusionary in cohort 1, whereas exclusion criteria in cohort 2 were a systolic AOBP greater than 160 mm Hg, diastolic BP greater than 100 mm Hg, or serum potassium level greater than 4.8 mmol/L.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.4-4"></a>

#### Registered inclusion and exclusion criteria

> “Background antihypertensive treatment of ≥ 2 drugs”
> “Serum cortisol ≥ 18 mcg/dL”
> “Subjects with body mass index > 40 kg/m2”
> “Subjects who, in the opinion of the investigator, have suspected nonadherence to antihypertensive treatment”
> “Strong CYP3A and CYP3A4 inducers”
> “Subjects who are night-shift workers”

Source: [ClinicalTrials.gov NCT05001945](https://clinicaltrials.gov/study/NCT05001945)

<a id="heading-3.1.4.5"></a>

### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

#### Cohort 1: five lorundrostat regimens or placebo

> “Cohort 1 participants were randomly assigned in a 1:1:1:1:1:1 ratio to placebo or 1 of 5 lorundrostat doses (12.5 mg, 50 mg, or 100 mg once daily or 12.5 mg or 25 mg twice daily).”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.5-2"></a>

#### Cohort 2: lorundrostat 100 mg once daily or placebo

> “In the second cohort, participants were randomized in a 1:6 ratio to placebo or lorundrostat, 100 mg once daily.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.5-3"></a>

#### Oral tablets for 8 weeks

> “MLS-101 tablet(s) by mouth once or twice daily.”
> “Placebo tablet(s) by mouth once or twice daily.”

Source: [ClinicalTrials.gov NCT05001945](https://clinicaltrials.gov/study/NCT05001945)

> “Participants received 50 mg of lorundrostat once daily, taken orally, for 8 weeks in Part 1 of the study”
> “Participants received 100 mg of lorundrostat once daily, taken orally, for 8 weeks in Part 2 of the study”

Source: [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)

<a id="topic-3.1.4.5-4"></a>

#### Add-on to stable background antihypertensive therapy with morning dosing

> “Five active doses of lorundrostat (12.5mg once daily QD, 50mg QD, 100mg QD, 12.5mg twice daily [BID], and 25mg BID) were compared to placebo in hypertensive subjects.”

Source: [Mineralys Therapeutics press release, Target-HTN JAMA publication (2023)](https://ir.mineralystx.com/news-events/press-releases/detail/26/mineralys-therapeutics-announces-jama-publication-of-full)

> “MLS-101 demonstrating substantial placebo-adjusted reduction in blood pressure for 24 hours with once-daily, morning dosing”

Source: [Mineralys Therapeutics press release, Target-HTN topline results (2022)](https://ir.mineralystx.com/news-events/press-releases/detail/5/mineralys-therapeutics-announces-positive-topline-phase-2)

<a id="heading-3.1.4.6"></a>

### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

#### 3.1.4.6.1 Rationale for Using Change in Office Systolic Blood Pressure as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

##### Primary endpoint: change in automated office systolic blood pressure at week 8

> “The primary efficacy end point was change in systolic AOBP from baseline to the end of study week 8.”
> “Efficacy assessment with AOBP (average of the last 2 of 5 unattended measurements using an automated oscillometric sphygmomanometer device after approximately 5 minutes of rest in a seated position) was measured weekly throughout the study.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.6.1-2"></a>

##### Registered primary outcome measure

> “Change From Baseline in Office-measured Systolic Blood Pressure (SBP) at Study Week 8 Compared to Placebo”
> “A least-square estimate of the mean difference between each dose group and the placebo group is provided for Week 8.”

Source: [ClinicalTrials.gov NCT05001945](https://clinicaltrials.gov/study/NCT05001945)

<a id="topic-3.1.4.6.1-3"></a>

##### Blood pressure reduction as the basis of cardiovascular benefit

> “The similar effects with multiple drug classes with disparate mechanisms of action indicate that it is the decrease in blood pressure, rather than any other property of the drugs, that is largely responsible for these benefits.”
> “Systolic pressure may be more important than diastolic pressure, especially in the elderly.”

Source: [FDA guidance, hypertension labeling for cardiovascular outcome claims (2011)](https://www.fda.gov/media/134777/download)

<a id="topic-3.1.4.6.1-4"></a>

##### Systolic blood pressure reduction and major cardiovascular events

> “a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease”

Source: [Blood Pressure Lowering Treatment Trialists' Collaboration (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8102467/)

<a id="topic-3.1.4.6.1-5"></a>

##### Unattended automated office blood pressure measurement

> “AOBP can be performed with or without staff being present, which is referred to as attended and unattended AOBP, respectively.”
> “Several studies have reported that BP measured with AOBP versus the auscultatory method is closer to awake out-of-office BP levels measured with ambulatory BP monitoring (ABPM).”
> “Because having an observer present when BP readings are obtained may lead to inaccurate values (eg, if the patient or observer is talking), it is preferred to have the patient in a room alone for BP measurements (ie, unattended AOBP).”

Source: [Muntner et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11409525/)

<a id="topic-3.1.4.6.1-6"></a>

##### Secondary efficacy endpoints

> “Secondary efficacy end points included changes in diastolic AOBP, 24-hour ambulatory BP monitoring changes, and the proportion of participants achieving an AOBP less than 130/80 mm Hg at week 7 or 8.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.6.1-7"></a>

##### Registered secondary outcome measures

> “Change in 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean Systolic Blood Pressure (SBP) and Mean Diastolic Blood Pressure (DBP) From Baseline to End of Treatment (EoT)”
> “Week 8 Change From Baseline in Office-measured Diastolic Blood Pressure (DBP)”
> “Number of Participants With Blood Pressure ≤ 130/80 mmHg at Week 8”
> “Each participant was assessed as a success if the Week 8 value for SBP was ≤130 mmHg and DBP ≤80 mmHg; subjects not meeting both these thresholds were assessed as a failure. Subjects missing an assessment at Week 8 or who received rescue medications were also considered failures.”

Source: [ClinicalTrials.gov NCT05001945](https://clinicaltrials.gov/study/NCT05001945)

<a id="topic-3.1.4.6.1-8"></a>

##### Safety, pharmacodynamic, and adverse events of special interest endpoints

> “Additional safety and pharmacodynamic biomarker end points included changes in PRA, serum aldosterone, cortisol, potassium, and eGFR during the study. Prespecified adverse events of special interest were incidence of hyperkalemia with dose modification, hypotension with symptoms, and adrenal insufficiency.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.6.1-9"></a>

##### Prespecified exploratory subgroups

> “Prespecified subgroups of interest examined the impact of BMI and concomitant administration of a thiazide-type diuretic on the degree of BP lowering.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="heading-3.1.4.7"></a>

### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

#### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

##### Sample size rationale

> “The study was designed to provide information regarding a safe and effective dose of lorundrostat for subsequent efficacy trials.”
> “A sample size of 30 participants per group was estimated to provide the half-width of the 2-sided 90% CI of 3.8 mm Hg with a common standard deviation assumed to be 9 mm Hg.”
> “All analyses of cohort 2 of the study were exploratory in nature, and no formal sample size considerations were undertaken for this cohort.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.7.1-2"></a>

##### Participants screened and randomized

> “From July 2021 through June 2022, a total of 380 patients were screened (n = 307 in cohort 1; n = 73 in cohort 2) and 200 participants underwent randomization (n = 163 in cohort 1; n = 37 in cohort 2).”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.7.1-3"></a>

##### Registered enrollment

| Field | Quoted record |
| --- | --- |
| Enrollment (actual) | “200” |

Source: [ClinicalTrials.gov NCT05001945](https://clinicaltrials.gov/study/NCT05001945)

<a id="topic-3.1.4.7.1-4"></a>

##### Participants randomized and analyzed for the primary endpoint by group

| Group | Randomized (baseline table) | Primary end point analysis (efficacy table) |
| --- | --- | --- |
| Cohort 1, lorundrostat 100 mg once daily | “100 mg once daily (n = 30)” | “100 mg once daily (n = 25)” |
| Cohort 1, lorundrostat 50 mg once daily | “50 mg once daily (n = 28)” | “50 mg once daily (n = 28)” |
| Cohort 1, lorundrostat 25 mg twice daily | “25 mg twice daily (n = 30)” | “25 mg twice daily (n = 28)” |
| Cohort 1, lorundrostat 12.5 mg twice daily | “12.5 mg twice daily (n = 22)” | “12.5 mg twice daily (n = 19)” |
| Cohort 1, lorundrostat 12.5 mg once daily | “12.5 mg once daily (n = 23)” | “12.5 mg once daily (n = 19)” |
| Cohort 1, placebo | “Placebo (n = 30)” | “Placebo (n = 29)” |
| Cohort 2, lorundrostat 100 mg once daily | “Lorundrostat, 100 mg once daily (n = 31)” | “Lorundrostat, 100 mg once daily (n = 31)” |
| Cohort 2, placebo | “Placebo (n = 6)” | “Placebo (n = 6)” |

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="heading-3.1.4.7.2"></a>

#### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

##### Full analysis set and safety population

> “Analyses were based on the full analysis set, defined as all randomized participants who received at least 1 dose of study medication. A safety analysis population was defined as all participants who took at least 1 dose of study drug.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.7.2-2"></a>

##### Mixed-model repeated-measures primary analysis

> “The primary efficacy analysis was performed using a mixed-model repeated-measures approach with fixed effects of categorical terms for treatment, week, and treatment by week interaction, and baseline systolic AOBP as a fixed continuous covariate.”
> “Analysis of the primary end point was repeated in each prespecified subgroup, and these analyses were considered exploratory.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.7.2-3"></a>

##### Handling of intercurrent events

> “The statistical analysis plan outlined intercurrent events (ICE) that would result in imputation of week 8 BP. Specifically, if rescue BP medications were initiated, the observed systolic BP at time of rescue medication initiation was imputed. Additionally, if participant withdrawal occurred before completion of the 8-week period for a treatment-related reason or worsening, the baseline systolic BP value was imputed as the week 8 measurement.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.7.2-4"></a>

##### Secondary analyses and multiplicity

> “All secondary efficacy end-point analyses are considered supportive, and any inferential statistics are considered descriptive in nature. No adjustment for multiplicity was performed due to the phase 2 exploratory intent of the trial.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.7.2-5"></a>

##### Registered analysis populations and cohort 2 comparison

> “The Baseline Analysis Population consisted of all randomized subjects.”
> “The full analysis set included all randomized subjects who received at least 1 dose of randomized study treatment (lorundrostat or placebo). Subjects were analyzed according to the randomized study treatment group.”
> “Per the study SAP, modelled analysis comparisons for Part 2 were performed for 100 mg QD Part 2 vs 100mg QD Part 1, and not to Placebo - Part 2. Accordingly, while subjects were analyzed, modelled LSmeans for Placebo - Part 2 were not reported.”

Source: [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)

<a id="heading-3.1.4.8"></a>

### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

#### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

##### Registered participant flow by group

| Disposition | Placebo, Part 1 | 12.5 mg BID, Part 1 | 25 mg BID, Part 1 | 12.5 mg QD, Part 1 | 50 mg QD, Part 1 | 100 mg QD, Part 1 | Placebo, Part 2 | 100 mg QD, Part 2 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Started | “30” | “22” | “30” | “23” | “28” | “30” | “6” | “31” |
| Completed | “29” | “18” | “28” | “18” | “26” | “27” | “6” | “30” |
| Not completed | “1” | “4” | “2” | “5” | “2” | “3” | “0” | “1” |
| Adverse event | “0” | “0” | “0” | “1” | “0” | “0” | “0” | “0” |
| Lost to follow-up | “0” | “1” | “1” | “2” | “0” | “1” | “0” | “0” |
| Not specified by investigator | “0” | “3” | “0” | “0” | “1” | “0” | “0” | “0” |
| Protocol violation | “1” | “0” | “1” | “1” | “0” | “1” | “0” | “0” |
| Withdrawal by subject | “0” | “0” | “0” | “1” | “1” | “1” | “0” | “1” |

Source: [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)

<a id="topic-3.1.4.8.1-2"></a>

##### Lowest-dose groups closed after the interim analysis

> “Following the completion of the planned interim analysis, the two lowest doses in Part 1 (i.e., 12.5 mg QD and 12.5 mg BID) were dropped from the study and no further subjects were enrolled in these treatment arms.”

Source: [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)

<a id="topic-3.1.4.8.1-3"></a>

##### Intercurrent events by group

> “In the primary analysis population of cohort 1, participants receiving lorundrostat had ICE as follows: 100 mg once daily: 1 had ICE type 1 (initiation of rescue medication; systolic BP that triggered rescue medication is imputed), 4 had ICE type 3 (withdrawal from treatment for treatment-related reason or worsening; baseline systolic BP is imputed), and 3 had ICE type 4 (withdrawal from treatment for non–treatment-related reasons; mixed-model repeated-measures estimate); 50 mg once daily: 1 had ICE type 1; 25 mg twice daily: 1 had ICE type 3 and 2 had ICE type 4; 12.5 mg twice daily: 1 had ICE type 3; and 12.5 mg once daily: 1 had ICE type 1, 4 had ICE type 3, and 4 had ICE type 4. In the placebo group, 1 had ICE type 1 and 1 had ICE type 4. In the primary analysis population of cohort 2 receiving lorundrostat, 2 had ICE type 1, 2 had ICE type 3, and 1 had ICE type 4.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.1-4"></a>

##### Screening outside the run-in

> “Seven participants were inadvertently screened following prescreening failure and did not participate in run-in.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="heading-3.1.4.8.2"></a>

#### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

##### Demographics and baseline blood pressure of randomized participants

> “Among randomized participants, the mean age was 65.7 (SD, 10.2) years, 60% were women, 36% were Black or African American, and 48% were of Hispanic or Latino ethnicity. At the time of randomization, 48% of participants had a body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) of greater than 30 and 40% had type 2 diabetes. Three or more antihypertensive medications were taken by 42% of the study population.”
> “Cohort 1 participants had a mean baseline systolic AOBP of 142.2 (SD, 12.5) mm Hg and a mean diastolic AOBP of 81.5 (SD, 9.7) mm Hg, whereas cohort 2 participants had a mean baseline systolic BP of 139.1 (SD, 8.7) mm Hg and diastolic BP of 79.1 (SD, 9.7) mm Hg.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.2-2"></a>

##### Baseline characteristics by group

| Characteristic | Cohort 1, 100 mg QD (n = 30) | Cohort 1, 50 mg QD (n = 28) | Cohort 1, 25 mg BID (n = 30) | Cohort 1, 12.5 mg BID (n = 22) | Cohort 1, 12.5 mg QD (n = 23) | Cohort 1, placebo (n = 30) | Cohort 2, 100 mg QD (n = 31) | Cohort 2, placebo (n = 6) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Age, mean (SD), y | “68.7 (8.9)” | “64.7 (9.5)” | “64.8 (9.7)” | “68.1 (10.1)” | “65.2 (11.3)” | “62.6 (10.7)” | “66.6 (10.6)” | “62.7 (12.3)” |
| Female, No. (%) | “18 (60.0)” | “15 (53.6)” | “19 (63.3)” | “14 (63.6)” | “12 (52.2)” | “17 (56.7)” | “21 (67.7)” | “4 (66.7)” |
| Black or African American, No. (%) | “15 (50.0)” | “8 (28.6)” | “7 (23.3)” | “7 (31.8)” | “11 (47.8)” | “16 (53.3)” | “6 (19.4)” | “2 (33.3)” |
| White, No. (%) | “14 (46.7)” | “19 (67.9)” | “23 (76.7)” | “15 (68.2)” | “11 (47.8)” | “13 (43.3)” | “25 (80.6)” | “4 (66.7)” |
| Hispanic or Latino ethnicity, No. (%) | “16 (53.3)” | “14 (50.0)” | “17 (56.7)” | “7 (31.8)” | “10 (43.5)” | “12 (40.0)” | “17 (54.8)” | “2 (33.3)” |
| Body mass index, mean (SD) | “30.4 (5.5)” | “32.0 (5.0)” | “30.6 (5.5)” | “32.0 (5.2)” | “30.6 (4.9)” | “31.9 (5.0)” | “30.5 (4.4)” | “32.0 (3.9)” |
| Systolic AOBP at randomization, mean (SD), mm Hg | “142.2 (13.4)” | “140.0 (12.1)” | “142.8 (13.1)” | “142.6 (13.3)” | “142.9 (13.7)” | “142.9 (10.7)” | “139.8 (9.1)” | “135.3 (5.5)” |
| Diastolic AOBP at randomization, mean (SD), mm Hg | “78.5 (10.0)” | “84.7 (7.0)” | “80.1 (9.3)” | “81.6 (9.4)” | “80.3 (12.0)” | “83.8 (9.5)” | “78.6 (10.0)” | “81.5 (7.9)” |
| eGFR, mean (SD), mL/min/1.73 m2 | “77.4 (14.0)” | “77.2 (14.1)” | “80.9 (12.4)” | “81.7 (16.3)” | “77.9 (18.7)” | “81.6 (17.3)” | “79.9 (13.1)” | “83.9 (18.6)” |
| Diabetes, No. (%) | “8 (26.7)” | “8 (28.6)” | “11 (36.7)” | “9 (40.9)” | “11 (47.8)” | “14 (46.7)” | “16 (51.6)” | “2 (33.3)” |
| Heart failure, No. (%) | “1 (3.3)” | “1 (3.6)” | “1 (3.3)” | “1 (4.5)” | “1 (4.3)” | “0” | “0” | “0” |
| 2 background BP medications, No. (%) | “14 (46.7)” | “20 (71.4)” | “14 (46.7)” | “7 (31.8)” | “14 (60.9)” | “17 (56.7)” | “20 (64.5)” | “4 (66.7)” |
| 3 or more background BP medications, No. (%) | “16 (53.3)” | “8 (28.6)” | “16 (53.3)” | “15 (68.2)” | “9 (39.1)” | “13 (43.3)” | “11 (35.5)” | “2 (33.3)” |
| Thiazide-type diuretic use, No. (%) | “17 (56.7)” | “16 (57.1)” | “18 (60.0)” | “13 (59.1)” | “12 (52.2)” | “16 (53.3)” | “19 (61.3)” | “5 (83.3)” |
| ACE inhibitor or ARB use, No. (%) | “23 (76.7)” | “20 (71.4)” | “27 (90.0)” | “17 (77.3)” | “18 (78.3)” | “22 (73.3)” | “30 (96.8)” | “5 (83.3)” |

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.2-3"></a>

##### Registered age distribution and region of enrollment

| Characteristic | Total (200 participants) |
| --- | --- |
| Age younger than 65 years | “83” |
| Age 65 to 79 years | “104” |
| Age 80 years or older | “13” |
| Enrolled in the United States | “200” |
| Body mass index, mean (SD), kg/m^2 | “31.1(5.0)” |
| Seated automated office systolic blood pressure, mean (SD), mmHg | “141.6(12.0)” |

Source: [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)

<a id="heading-3.1.4.8.3"></a>

#### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

##### Primary end point: automated office systolic blood pressure at week 8

| Measure | Cohort 1, 100 mg QD (n = 25) | Cohort 1, 50 mg QD (n = 28) | Cohort 1, 25 mg BID (n = 28) | Cohort 1, 12.5 mg BID (n = 19) | Cohort 1, 12.5 mg QD (n = 19) | Cohort 1, placebo (n = 29) | Cohort 2, 100 mg QD (n = 31) | Cohort 2, placebo (n = 6) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline SBP, mean (SD), mm Hg | “143.8 (12.0)” | “141.8 (10.9)” | “140.9 (9.6)” | “144.6 (10.5)” | “147.1 (11.6)” | “142.7 (10.2)” | “140.4 (8.6)” | “132.9 (8.4)” |
| Week 8 SBP, mean (SD), mm Hg | “131.3 (14.1)” | “128.6 (13.7)” | “131.3 (16.6)” | “131.9 (12.9)” | “140.8 (22.0)” | “139.1 (14.2)” | “129.3 (15.4)” | “128.3 (18.9)” |
| Change in SBP, least-squares mean (SE), mm Hg | “−11.9 (2.8)” | “−13.7 (2.7)” | “−11.1 (2.7)” | “−11.3 (3.2)” | “−5.6 (3.2)” | “−4.1 (2.6)” | “−11.4 (2.5)” | Not reported |
| Difference from placebo, least-squares mean (90% CI), mm Hg | “−7.8 (−14.1 to −1.5)” | “−9.6 (−15.8 to −3.4)” | “−7.0 (−13.1 to −0.8)” | “−7.2 (−14.0 to −0.4)” | “−1.5 (−8.3 to 5.3)” | Not applicable | Not reported | Not applicable |
| P value | “.04” | “.01” | “.06” | “.08” | “.71” | Not applicable | Not reported | Not applicable |

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.3-2"></a>

##### Placebo-subtracted change in systolic blood pressure with once-daily doses

> “At week 8, the placebo group demonstrated a change of −4.1 (SE, 2.6) mm Hg in systolic AOBP.”
> “In the once-daily dose cohorts, the placebo-subtracted change in systolic AOBP was −1.5 mm Hg (90% CI, −8.3 to 5.3 mm Hg; P = .71) for 12.5 mg, −9.6 mm Hg (90% CI, −15.8 to −3.4 mm Hg; P = .01) for 50 mg, and −7.8 mm Hg (90% CI, −14.1 to −1.5 mm Hg; P = .04) for 100 mg. The change in BP demonstrated with the twice-daily doses, compared with placebo, showed similar BP reduction.”
> “Because cohort 2 was an exploratory end point, no formal statistical testing was performed comparing lorundrostat with placebo.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.3-3"></a>

##### Observed changes in office systolic blood pressure in participants with suppressed renin

> “Following 8 weeks of treatment in participants with suppressed PRA, changes in office systolic blood pressure of −14.1, −13.2, −6.9, and −4.1 mm Hg were observed with 100 mg, 50 mg, and 12.5 mg once daily of lorundrostat and placebo, respectively. Observed reductions in systolic blood pressure in individuals receiving twice-daily doses of 25 mg and 12.5 mg of lorundrostat were −10.1 and −13.8 mm Hg, respectively.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.3-4"></a>

##### Topline placebo-adjusted reductions reported by Mineralys

> “Placebo-adjusted reduction in SBP of 1.4 mmHg (12.5 mg QD, p=NS), 9.7 mmHg (50 mg QD, p=0.010) and 7.9 mmHg (Part 1, 100 mg QD, p=0.037)”
> “Thiazide diuretic as part of background medications placebo-adjusted reduction in SBP of 5.3 mmHg (12.5 mg QD, p=NS), 13.2 mmHg (50 mg QD, p=0.010) and 11.4 mmHg (Part 1, 100 mg QD, p=0.028)”

Source: [Mineralys Therapeutics press release, Target-HTN topline results (2022)](https://ir.mineralystx.com/news-events/press-releases/detail/5/mineralys-therapeutics-announces-positive-topline-phase-2)

<a id="topic-3.1.4.8.3-5"></a>

##### Secondary end point: automated office diastolic blood pressure at week 8

| Measure | Cohort 1, 100 mg QD (n = 25) | Cohort 1, 50 mg QD (n = 28) | Cohort 1, 25 mg BID (n = 28) | Cohort 1, 12.5 mg BID (n = 19) | Cohort 1, 12.5 mg QD (n = 19) | Cohort 1, placebo (n = 29) | Cohort 2, 100 mg QD (n = 31) | Cohort 2, placebo (n = 6) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline DBP, mean (SD), mm Hg | “78.9 (9.6)” | “84.9 (6.4)” | “78.9 (8.0)” | “81.6 (7.6)” | “82.4 (10.7)” | “83.4 (8.8)” | “78.1 (7.6)” | “78.3 (7.6)” |
| Week 8 DBP, mean (SD), mm Hg | “73.0 (9.4)” | “76.8 (9.8)” | “75.4 (13.1)” | “75.2 (10.1)” | “81.4 (17.2)” | “81.3 (9.4)” | “72.2 (8.4)” | “76.2 (11.0)” |
| Change in DBP, least-squares mean (SE), mm Hg | “−5.8 (1.8)” | “−7.1 (1.7)” | “−4.1 (1.7)” | “−5.5 (2.0)” | “−3.8 (2.0)” | “−1.6 (1.7)” | “−5.6 (1.4)” | Not reported |
| Difference from placebo, least-squares mean (90% CI), mm Hg | “−4.1 (−8.1 to −0.1)” | “−5.5 (−9.4 to −1.5)” | “−2.5 (−6.4 to 1.4)” | “−3.8 (−8.2 to 0.5)” | “−2.1 (−6.5 to 2.2)” | Not applicable | Not reported | Not applicable |
| P value | “.09” | “.02” | “.30” | “.14” | “.42” | Not applicable | Not reported | Not applicable |

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

> “The 50-mg once-daily dose of lorundrostat decreased diastolic AOBP by 5.5 mm Hg compared with placebo (90% CI, −9.4 to −1.5 mm Hg; P = .02). Other doses did not demonstrate statistically significant lowering of diastolic AOBP compared with placebo.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.3-6"></a>

##### Secondary end point: ambulatory 24-hour blood pressure

> “Twenty-four-hour ambulatory BP monitoring results including mean overnight and central systolic BP as assessed by pulse-wave velocity are reported in eTables 3 and 4 in Supplement 2.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

| Measure | Placebo, Part 1 | 12.5 mg BID, Part 1 | 25 mg BID, Part 1 | 12.5 mg QD, Part 1 | 50 mg QD, Part 1 | 100 mg QD, Part 1 | Placebo, Part 2 | 100 mg QD, Part 2 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Participants analyzed | “26” | “16” | “26” | “15” | “28” | “24” | “0” | “27” |
| Change in 24-hour mean SBP, least squares mean (SE), mmHg | “-1.01(2.38)” | “-5.78(3.03)” | “-9.05(2.38)” | “-2.51(3.15)” | “-4.86(2.34)” | “-6.34(2.5)” | Not reported | “-1.02(2.64)” |
| Change in 24-hour mean DBP, least squares mean (SE), mmHg | “-0.90(1.46)” | “-5.14(1.85)” | “-6.03(1.45)” | “-2.34(1.91)” | “-3.64(1.40)” | “-6.14(1.51)” | Not reported | “-0.07(1.69)” |

Source: [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)

<a id="topic-3.1.4.8.3-7"></a>

##### Secondary end point: blood pressure below 130/80 mm Hg at week 8

> “The proportion of participants with AOBP of less than 130/80 mm Hg at trial conclusion did not statistically differ between treatment groups and placebo (eFigure 3 in Supplement 2).”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

| Measure | Placebo, Part 1 | 12.5 mg BID, Part 1 | 25 mg BID, Part 1 | 12.5 mg QD, Part 1 | 50 mg QD, Part 1 | 100 mg QD, Part 1 | Placebo, Part 2 | 100 mg QD, Part 2 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Participants analyzed | “30” | “22” | “30” | “23” | “28” | “30” | “6” | “31” |
| Participants with blood pressure ≤ 130/80 mmHg at week 8 | “7” | “7” | “13” | “6” | “12” | “9” | “3” | “17” |

Source: [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)

<a id="topic-3.1.4.8.3-8"></a>

##### Exploratory subgroups: obesity and thiazide-type diuretic use

> “Most notably, participants with obesity demonstrated greater BP lowering in response to lorundrostat. Individuals with a BMI greater than 30 randomized to 50 mg once daily of lorundrostat demonstrated a −16.7 mm Hg (90% CI, −25.5 to −7.9 mm Hg) change in systolic AOBP compared with placebo. With 100 mg once daily of lorundrostat, participants with obesity saw a −12.3 mm Hg (90% CI, −21.6 to −3.1 mm Hg) change in systolic AOBP compared with placebo. Among individuals with a BMI of 25 to 30, the BP changes were 2.2 mm Hg (90% CI, −7.4 to 11.8 mm Hg) and −4.5 (90% CI, −14.5 to 5.5 mm Hg) for the 50-mg and 100-mg once-daily doses, respectively.”
> “Similarly, participants taking a thiazide-type diuretic randomized to 50 mg or 100 mg once daily of lorundrostat demonstrated changes of −12.9 mm Hg (90% CI, −21.2 to −4.7 mm Hg) and −10.0 mm Hg (90% CI, −21.2 to −1.6 mm Hg) in systolic AOBP compared with placebo. Blood pressure decreases were attenuated among participants not taking a diuretic (eTable 1 in Supplement 2).”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.3-9"></a>

##### Exploratory cohort 2: participants without suppressed renin

> “Participants with PRA of greater than 1.0 ng/mL/h (cohort 2) randomized to 100 mg once daily of lorundrostat demonstrated a similar change in mean systolic AOBP of −11.4 (SD, 2.5) mm Hg compared with those randomized to 100 mg once daily with suppressed plasma renin in cohort 1. The least-squares mean systolic AOBP difference between the 100-mg once-daily cohorts was 0.74 mm Hg (90% CI, −5.4 to 6.9 mm Hg).”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.3-10"></a>

##### Pharmacodynamic biomarkers: aldosterone, renin activity, and cortisol

> “Lorundrostat resulted in reductions in serum aldosterone at all doses, whereas the cohort 1 placebo group saw an increase in mean serum aldosterone level of 0.14 (SD, 3.68) ng/dL. The 12.5-mg, 50-mg, and 100-mg once-daily doses in cohort 1 reduced mean serum aldosterone by 1.05 (SD, 4.33) ng/dL, 2.56 (SD, 3.72) ng/dL, and 2.88 (SD, 4.44) ng/dL, respectively.”
> “In cohort 2, 100 mg daily of lorundrostat decreased mean serum aldosterone by 1.19 (SD, 5.38) ng/dL. Anticipated increases in PRA were observed ranging between 0.78 (SD, 3.44) ng/mL/h to 4.65 (SD, 11.27) ng/mL/h in cohort 1, and there were small increases in serum cortisol (eTable 2 in Supplement 2).”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.3-11"></a>

##### Once-daily compared with twice-daily dosing

> “The 50-mg once-daily dose of lorundrostat lowered office BP to a similar degree as the 100-mg once daily dose, but resulted in fewer adverse events, including fewer episodes of hyperkalemia. Lorundrostat has a relatively short half-life, and once-daily dosing resulted in a 25% lower mean change in serum potassium when 50 mg once daily was compared with 25 mg twice daily.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="heading-3.1.4.8.4"></a>

#### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

#### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

##### Deaths, serious adverse events, and overall adverse events

> “No participant deaths occurred during the trial. Three serious adverse events occurred; only 1 was deemed treatment related. A participant randomized to 100 mg once daily of lorundrostat in cohort 2 had worsening of hyponatremia necessitating stopping the drug. A total of 110 participants (55%) experienced any adverse event during the trial (Table 3). Most adverse events were classified as mild by investigators.”
> “One participant was identified with worsening of preexisting coronary artery disease and 1 participant was found to have metastatic cancer in their peritoneum.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.5-2"></a>

##### Adverse events and serum potassium changes by group

| Measure | Cohort 1, 100 mg QD (n = 30) | Cohort 1, 50 mg QD (n = 28) | Cohort 1, 25 mg BID (n = 30) | Cohort 1, 12.5 mg BID (n = 22) | Cohort 1, 12.5 mg QD (n = 23) | Cohort 1, placebo (n = 30) | Cohort 2, 100 mg QD (n = 31) | Cohort 2, placebo (n = 6) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Any serious adverse event, No. (%) | “0” | “0” | “0” | “0” | “2 (9)” | “0” | “1 (3)” | “0” |
| Any adverse event, No. (%) | “17 (57)” | “12 (43)” | “20 (67)” | “13 (59)” | “16 (70)” | “12 (40)” | “19 (61)” | “1 (17)” |
| Hypotension, No. (%) | “1 (3)” | “0” | “0” | “1 (5)” | “0” | “0” | “1 (3)” | “0” |
| Change from baseline in serum potassium, mean (SD), mmol/L | “0.29 (0.59)” | “0.25 (0.36)” | “0.34 (0.46)” | “0.32 (0.53)” | “0.31 (0.44)” | “0.03 (0.37)” | “0.21 (0.54)” | “−0.05 (0.28)” |
| Serum potassium 5.6-6.0 mmol/L, No. (%) | “5 (16)” | “1 (4)” | “2 (7)” | “2 (9)” | “3 (13)” | “0” | “2 (6)” | “0” |
| Serum potassium 6.1-6.5 mmol/L, No. (%) | “0” | “0” | “1 (3)” | “1 (5)” | “1 (4)” | “0” | “1 (3)” | “0” |
| Serum potassium >6.5 mmol/L, No. (%) | “1 (3)” | “1 (4)” | “0” | “0” | “0” | “0” | “0” | “0” |

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.5-3"></a>

##### Hyperkalemia and hypotension

> “Prespecified adverse events of special interest included 3 participants (2%) with hypotension. Mean serum potassium increases were similar across all lorundrostat doses, including increases of 0.25 mmol/L in the 50-mg and 100-mg once-daily groups. Six participants (3.6%) had serum potassium levels above 6.0 mmol/L during the trial (Table 3). No instances of hyperkalemia required intervention beyond discontinuation or reduction in the dose of lorundrostat.”
> “Affected individuals were counted once at highest-grade abnormality. Hemolyzed blood samples with serum potassium levels that were not reproducible on repeat testing were not included.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.5-4"></a>

##### Cortisol and adrenal function

> “No adrenocortical insufficiency occurred during the trial. Cosyntropin stimulation testing in participants randomized to 100 mg once daily in both cohort 1 and cohort 2 was normal, with stimulated values of cortisol greater than 18 µg/dL in all individuals receiving cosyntropin (eFigure 4 in Supplement 2).”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.5-5"></a>

##### Estimated glomerular filtration rate

> “Declines in eGFR paralleled the reduction in systolic AOBP and were consistent with expected lowering of intraglomerular pressures (eTable 2 in Supplement 2).”
> “Examples of more prevalent adverse events included hyperkalemia and decline in estimated glomerular filtration rate.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.5-6"></a>

##### Registered serious and other adverse events by group

> “12 weeks; two weeks for Run-in Phase treatment-emergent adverse events (TEAEs) reporting and ten weeks for on-treatment (i.e., post-randomization) TEAE reporting.”

Source: [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)

| Adverse event, affected / at risk (%) | Placebo, Part 1 | 12.5 mg BID, Part 1 | 25 mg BID, Part 1 | 12.5 mg QD, Part 1 | 50 mg QD, Part 1 | 100 mg QD, Part 1 | Placebo, Part 2 | 100 mg QD, Part 2 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| All-cause mortality | “0/30 (0.00%)” | “0/22 (0.00%)” | “0/30 (0.00%)” | “0/23 (0.00%)” | “0/28 (0.00%)” | “0/30 (0.00%)” | “0/6 (0.00%)” | “0/31 (0.00%)” |
| Serious adverse events, total | “0/30 (0.00%)” | “0/22 (0.00%)” | “0/30 (0.00%)” | “2/23 (8.70%)” | “0/28 (0.00%)” | “0/30 (0.00%)” | “0/6 (0.00%)” | “1/31 (3.23%)” |
| Other adverse events, total | “7/30 (23.33%)” | “13/22 (59.09%)” | “18/30 (60.00%)” | “16/23 (69.57%)” | “10/28 (35.71%)” | “16/30 (53.33%)” | “1/6 (16.67%)” | “19/31 (61.29%)” |
| Hyperkalemia | “1/30 (3.33%)” | “5/22 (22.73%)” | “9/30 (30.00%)” | “6/23 (26.09%)” | “3/28 (10.71%)” | “8/30 (26.67%)” | “0/6 (0.00%)” | “8/31 (25.81%)” |
| Glomerular filtration rate decreased | “1/30 (3.33%)” | “3/22 (13.64%)” | “0/30 (0.00%)” | “1/23 (4.35%)” | “0/28 (0.00%)” | “5/30 (16.67%)” | “0/6 (0.00%)” | “1/31 (3.23%)” |
| Blood creatinine increased | “0/30 (0.00%)” | “0/22 (0.00%)” | “0/30 (0.00%)” | “0/23 (0.00%)” | “0/28 (0.00%)” | “3/30 (10.00%)” | “0/6 (0.00%)” | “1/31 (3.23%)” |
| Urinary tract infection | “0/30 (0.00%)” | “0/22 (0.00%)” | “3/30 (10.00%)” | “1/23 (4.35%)” | “2/28 (7.14%)” | “1/30 (3.33%)” | “0/6 (0.00%)” | “2/31 (6.45%)” |
| Hypotension | “0/30 (0.00%)” | “1/22 (4.55%)” | “0/30 (0.00%)” | “0/23 (0.00%)” | “0/28 (0.00%)” | “1/30 (3.33%)” | “0/6 (0.00%)” | “1/31 (3.23%)” |
| Orthostatic hypotension | “0/30 (0.00%)” | “1/22 (4.55%)” | “0/30 (0.00%)” | “2/23 (8.70%)” | “0/28 (0.00%)” | “0/30 (0.00%)” | “0/6 (0.00%)” | “0/31 (0.00%)” |
| Hypertension | “0/30 (0.00%)” | “0/22 (0.00%)” | “1/30 (3.33%)” | “2/23 (8.70%)” | “2/28 (7.14%)” | “0/30 (0.00%)” | “0/6 (0.00%)” | “0/31 (0.00%)” |
| Cortisol decreased | “1/30 (3.33%)” | “2/22 (9.09%)” | “1/30 (3.33%)” | “0/23 (0.00%)” | “0/28 (0.00%)” | “0/30 (0.00%)” | “0/6 (0.00%)” | “0/31 (0.00%)” |

Source: [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)

<a id="topic-3.1.4.8.5-7"></a>

##### Company summary of potassium findings

> “There was an anticipated, modest increase in serum potassium in the two active QD dose cohorts: 0.25 mmol/L in the 50 mg cohort, and 0.35 mmol/L in the 100 mg cohort. Six individuals across the five active dose cohorts experienced an instance of elevated potassium above 6 mmol/L. Per-protocol, study drug administration was reduced, temporarily held or discontinued and consistent with the short half-life of MLS-101; all episodes were rapidly reversible.”
> “An Independent Data Safety Monitoring Board expressed no concerns about the effect of MLS-101 on serum potassium in the Target-HTN trial.”

Source: [Mineralys Therapeutics press release, Target-HTN topline results (2022)](https://ir.mineralystx.com/news-events/press-releases/detail/5/mineralys-therapeutics-announces-positive-topline-phase-2)

> “Adverse events observed were a modest increase in serum potassium, decrease in estimated glomerular filtration rate, urinary tract infection and hypertension with one serious adverse event possibly related to study drug being hyponatremia.”

Source: [Mineralys Therapeutics press release, Target-HTN JAMA publication (2023)](https://ir.mineralystx.com/news-events/press-releases/detail/26/mineralys-therapeutics-announces-jama-publication-of-full)

<a id="heading-3.1.4.9"></a>

### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

#### Summary

Target-HTN was a phase 2, dose-ranging trial that randomized 200 participants at sites in the United States to five lorundrostat regimens or placebo for 8 weeks, with no adjustment for multiplicity and with treatment differences reported as 90% confidence intervals. In cohort 1, the primary analysis included 19 to 29 participants per group, and the authors state that “each studied dose had a limited sample size”. Randomization to the 12.5 mg once-daily and 12.5 mg twice-daily groups stopped after the January 2022 interim analysis, and two interim analyses were performed in total. Cohort 1 enrolled only participants with suppressed renin; cohort 2 (37 participants, 6 receiving placebo) was exploratory, with no formal statistical testing against placebo. Sustained hypertension was not confirmed by 24-hour ambulatory monitoring before randomization, which the authors associate with “a prominent white-coat effect” in the 50 mg once-daily group. Participants with an eGFR below 60 mL/min/1.73 m2, or with serum potassium above 5.2 mmol/L (cohort 1) or 4.8 mmol/L (cohort 2), were excluded. The registered results define the proportion at goal as blood pressure of 130/80 mmHg or lower at week 8, while the publication describes it as below 130/80 mm Hg at week 7 or 8. The trial protocol was designed by the sponsor, Mineralys Therapeutics, which also provided input on the manuscript.

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/); [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)

<a id="topic-3.1.4.9-2"></a>

#### Limitations stated by the authors

> “This trial has limitations. First, multiple dosing regimens were tested for efficacy, and each studied dose had a limited sample size. Second, 24-hour ambulatory BP monitoring was not used to confirm sustained hypertension before randomization, and this resulted in a disproportionate percentage of participants with a prominent white-coat effect in the 50-mg once-daily lorundrostat group. Third, cohort 1 of this trial selected participants with suppressed renin at baseline.”
> “Fourth, 2 interim analyses were performed; multiple interim analyses would not be appropriate in subsequent confirmatory trials.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.9-3"></a>

#### Need for confirmatory studies

> “Among individuals with uncontrolled hypertension, use of lorundrostat was effective at lowering blood pressure compared with placebo, which will require further confirmatory studies.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.9-4"></a>

#### Registered limitations and caveats

> “Following the completion of the planned interim analysis in January 2022, the two lowest doses in Part 1 (i.e., 12.5 mg QD and 12.5 mg BID) were dropped from the study and no further subjects were enrolled in these treatment arms. Accordingly, overall subject numbers in these arms is less than originally planned.”

Source: [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)

<a id="topic-3.1.4.9-5"></a>

#### Sponsor role in the protocol and manuscript

> “The trial protocol was designed by Mineralys Therapeutics.”
> “The first author (L.J.L.) wrote the first version of the manuscript and made revisions following input from coauthors and the sponsor.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.9-6"></a>

#### Publication restrictions on investigators

> “There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed”

Source: [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
